Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Amicus Therapeutics (NASDAQ:FOLD) has received mixed reviews from 6 financial analysts over the past quarter, with ratings ranging from bullish to bearish. The average 12-month price target is $17.5, with a high of $22.00 and a low of $13.00, marking a 6.67% decline from the previous average. Analysts have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market conditions. Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing strong market position, revenue growth, and financial performance despite some challenges in ROE and a high debt-to-equity ratio.
May 14, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amicus Therapeutics has received a mix of bullish and bearish ratings from analysts, with a revised average price target of $17.5. The company's focus on rare metabolic diseases and its financial performance, including revenue growth and market capitalization, suggest a strong position despite some financial challenges.
The mixed analyst ratings and the slight decline in the average price target could lead to short-term uncertainty in stock performance. However, the company's strong market position and revenue growth in the rare metabolic diseases sector may counterbalance concerns about its financial challenges, such as high debt levels and below-average ROE.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100